NOVARTIS AG-SPONSORED ADR
NVSNYSETrading Snapshot
- Day Range
- $154.11 – $157.41
- 52-Week Range
- $121.57 – $170.46
- Volume (shares)
- 1,945,308
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.89B
- Next Earnings
- 2027-02-02
Fundamentals Snapshot
- Annual Revenue
- $54.81B
- Last Q Revenue
- $14.42B
- P/E Ratio
- 30.0
- P/S Ratio
- 5.4x
- EPS (TTM)
- $5.23
- Dividend Yield
- 2.86%
- Dilution (1yr)
- −3.7%
NOVARTIS AG-SPONSORED ADR
NVS
StockOtter · stockotter.spaceAbout NOVARTIS AG-SPONSORED ADR
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
What Novartis (NVS) Said on Its Q3 Earnings Call
Novartis NYSE: NVS reported third-quarter sales growth and margin expansion, supported by demand for priority medicines and productivity initiatives, while raising its full-year outlook for core operating income.
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
NVS' Q3 Earnings Top Estimates on Strong Key Drug Sales, Revenues Miss
Novartis beats Q3 earnings estimates and raises its 2026 operating income outlook as Kisqali, Kesimpta and Scemblix offset generic competition.
Novartis Says 'Well on Track' for Long-Term Outlook Despite $1.9 Billion Avidity Hit
Novartis AG (NYSE:NVS) reported mixed third-quarter earnings on Tuesday as the prized Avidity Biosciences deal worth $12 billion cost the company an estimated $1.9 billion in impairment charges, primarily driven by the t
Novartis (NVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and th